A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma

Systemic chemotherapy remains the mainstay of treatment for patients with unresectable malignant pleural mesothelioma (MPM). In 2003, the EMPHACIS trial established cisplatin and pemetrexed as the standard of care for first-line treatment of advanced mesothelioma [1]. More recently, the MAPS trial provided the first randomised demonstration of efficacy of a targeted therapy in mesothelioma, with the addition of bevacizumab to cisplatin and pemetrexed chemotherapy providing a small incremental survival benefit over chemotherapy alone, increasing median survival from16.1 to 18.8 months [2].

Source: Lung Cancer - December 30, 2019 Category: Cancer & Oncology Authors: Wei-Sen Lam, Jenette Creaney, Fred K. Chen, Wee Loong Chin, Sanjeevan Muruganandan, Sukanya Arunachalam, Mary S. Attia, Catherine Read, Kevin Murray, Michael Millward, Jon Spiro, Aron Chakera, Y.C. Gary Lee, Anna K. Nowak Source Type: research